PCI Biotech Holding ASA (FRA:4QG) Additional Paid-In Capital : €1.90 Mil(As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Additional Paid-In Capital?

PCI Biotech Holding ASA's quarterly additional paid-in capital declined from Dec. 2023 (€3.30 Mil) to Jun. 2024 (€0.00 Mil) but then increased from Jun. 2024 (€0.00 Mil) to Dec. 2024 (€1.90 Mil).

PCI Biotech Holding ASA's annual additional paid-in capital increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€3.30 Mil) but then declined from Dec. 2023 (€3.30 Mil) to Dec. 2024 (€1.90 Mil).

PCI Biotech Holding ASA Additional Paid-In Capital Historical Data

The historical data trend for PCI Biotech Holding ASA's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Additional Paid-In Capital Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

42.53

44.39

3.30

1.90

PCI Biotech Holding ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	3.30	-	1.90

PCI Biotech Holding ASA Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

PCI Biotech Holding ASA Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

PCIB:Norway 0JGL:UK

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines